Effect of different polymers on release of ranolazine from extended release tablets
Main Article Content
Abstract
thereby reduce dosing frequency, improve patient compliance and reduce the dose‑related side‑effects. Ranolazine is
indicated for the chronic treatment of angina in patients who have not achieved an adequate response with other anti‑anginal
agent. The present investigation was undertaken to design the extended release tablets of ranolazine employing different
polymers as matrix forming agents using direct compression technique. Formulated tablets were evaluated for weight
variation, hardness, friability, drug content, swelling index and in vitro release studies. The drug release followed first order
kinetics and controlled by both erosion and diffusion mechanism. It is concluded that the desired drug release pattern can be obtained from the formulation containing 9.8% w/w eudragit and 39.2% w/w metallose offered relatively much slow release of ranolazine compared with other formulations. The selected formulation showed a similarity factor 76 when
comparing in vitro dissolution data of the commercial formulation ranozex 500.
Key words: Anti‑anginal, diffusion mechanism, direct compression technique, matrix forming
Downloads
Article Details
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
References
Remington. The Science and Practice of Pharmacy. 21st ed.
USA: Lippincott, Williams and Wilkins Publications; 2005. p. 939‑64.
Thomasan. Physician Desk Reference. 61st ed. Montvale, New Jersy:
Thomson PDR; 2007. p. 1035‑37.
Rodriguez FC, Bruneau N, Barra J, Alfonso D, Doelker E. Hydrophillic
cellulose derivatives as drug delivery carrier: Influence of substitution
type on the properties of compressed matrix tablets. In: Wise DL,
editor. Handbook of Pharmaceutical Controlled Release Technology.
New York: Marcel Dekker; 2000. p. 1‑30.
Lee PI. Diffusional release of a solute from polymeric matrix–
approximate analytical solutions. J Membrane Sci 1980;7255‑75.
Tiwari S, Rajabi‑Siahboomi AR. Extended–release oral drug delivery
systems. In: Jain KK, editor. Totowa, NJ, New York: Humana Press; 2008.
p. 217‑43.
Vass S, Deng H, Rajabi‑Siahboomi AR. Investigation of ethylcellulose in
the preparation of theophylline extended release inert matrix tablets.
AAPS Annual Meeting Exposition. 2008.
Ruiz NR, Ghaly ES. Mechanism of drug release from matrices prepared
with aqueous dispersion of ethylcellulose. Drug Dev Ind Pharm
;23:113‑7.
Subrahmanyam CV. Essentials of Physical Pharmacy. 1st ed.
New Delhi: Vallabh Publications; 2007.
Indian Pharmacopoeia 1996. Vol. 2. New Delhi: Ministry of Health and
Family Welfare, The Controller of Publications; 1996. p. 750.
USP 27/NF 22. Rockville: United States Pharmacopeial Convention;
p. 2621.
Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of
Industrial Pharmacy. 3rd ed. Bombay: Varghese Publishing House; 1987.
p. 297.
Mohamed, Roni A. In‑vitro release kinetics study of ranolazine
from swellable hydrophilic matrix tablets. Dhaka Univ J Pharma Sci
;8:31‑8.
Kale VV, Kasliwal R, Parada SK, Aearia JG. Formulation and release
characterstics of guar gum tablets containing metformin hydrocholide.
Int J Pharm Exci 2004;75‑80.
Higuchi T. Mechanism of sustained‑action medication. Theoretical
analysis of rate of release of solid drugs dispersed in solid matrices.
J Pharm Sci 1963;52:1145‑9.